Cite
HARVARD Citation
Thielmann, C. et al. (2022). TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European journal of cancer. pp. 99-107. [Online].